.
lawmakers should revisit that idea when lepage is no longer in office next year..
orchid pharma faces liquidation as lenders reject resolution plan
.
5 / 5
.
in a news release, the drug's manufacturer, amgen, said the list price will be 5 a month or ,900 annually. costs to patients may vary depending on insurance..
all programs
.viewpoint: china has the upper hand in cancer cell therapy